title: Prognostic molecular markers in myelodysplastic syndromes.
abstract: Cytogenetic findings in myelodysplastic syndromes play an important role in diagnosis, prognostication and clinical decision making. Therefore, they became an important aspect in scoring systems such as the International Prognostic Scoring System (IPSS) and the WHO-adapted Prognostic Scoring System (WPSS). Ongoing efforts to refine the categorization of karyotypes with regard to prognosis and therapeutic options will change scoring systems in the near future. In order to learn more about the pathophysiology of myelodysplastic syndromes, various molecular genetic aberrations are identified and their impact on prognosis discussed. New screening methods such as gene expression or single nucleotide polymorphism analysis are good candidates to find entrance in clinical practice in the future as they are useful tools in further elucidation of the underlying defects in myelodysplastic syndromes and the development of more specific classifications of the disease concerning risk assessment.
authors.affiliation: Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Duesseldorf, Moorenstraße 5, Düesseldorf, Germany. judith.neukirchen@med.uni-duesseldorf.de
authors.forename: Judith
authors.initials: J
authors.lastname: Neukirchen
authors.forename: Rainer
authors.initials: R
authors.lastname: Haas
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
mesh_terms: D000818:Animals; D003582:Cytogenetics; D020869:Gene Expression Profiling; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D040901:Proteomics